BLU945   Click here for help

GtoPdb Ligand ID: 11948

Synonyms: BLU 945 | BLU-945 | Compound 150 [WO2021133809A1]
Compound class: Synthetic organic
Comment: BLU945 is a potent, non-covalent, and orally available EGFR inhibitor (4th generation), that was designed to inhibit the EGFR pathway and provide anti-tumour activity in NSCLC with EGFR resistance mutations (EGFR with T790M/C797S triple mutant; confers resistance to the 3rd generation EGFR inhibitor osimertinib). Its structure was revealed during the 'first disclosure' session at the ACS Spring 2022 meeting, and this was matched by the Guide to PHARMACOLOGY team to one of the structures (compound 150) in Blueprint Medicines' patent WO2021133809A1 [1]
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 1
Rotatable bonds 8
Topological polar surface area 108.93
Molecular weight 556.26
XLogP 6
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES CO[C@@H]1CCN(C[C@@H]1F)c1nccc(n1)Nc1ncc2c(c1)c(ccc2N1C[C@@H]([C@H]1C)CS(=O)(=O)C)C(C)C
Isomeric SMILES CO[C@@H]1CCN(C[C@@H]1F)c1nccc(Nc2ncc3c(ccc(C(C)C)c3c2)N2C[C@H](CS(=O)(=O)C)[C@H]2C)n1
InChI InChI=1S/C28H37FN6O3S/c1-17(2)20-6-7-24(35-14-19(18(35)3)16-39(5,36)37)22-13-31-27(12-21(20)22)32-26-8-10-30-28(33-26)34-11-9-25(38-4)23(29)15-34/h6-8,10,12-13,17-19,23,25H,9,11,14-16H2,1-5H3,(H,30,31,32,33)/t18-,19-,23+,25-/m1/s1
No information available.
Summary of Clinical Use Click here for help
BLU945 has advanced to early stage clinical evaluation.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04862780 (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC Phase 1/Phase 2 Interventional Blueprint Medicines Corporation